PRKACG

cAMP-dependent protein kinase catalytic subunit gamma · P22612 · PRKACG on Sugi Atlas →

25,777 patent compounds predicted against PRKACG, 18,508 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gf-109203 (SCHEMBL338086)	1.00	13/20
Gf-109203 (SCHEMBL1199513)	0.98	13/20
Balanol (SCHEMBL62128)	1.00	10/20
Balanol (SCHEMBL62129)	1.00	10/20
Ucn-01 (SCHEMBL259162)	1.00	8/20
SCHEMBL224940	0.56	7/20
Staurosporine (SCHEMBL8156)	1.00	6/20
Staurosporine (SCHEMBL8157)	1.00	6/20
Staurosporine (SCHEMBL624944)	0.93	6/20
SCHEMBL190590	1.00	5/20
Hydrochloric Acid (SCHEMBL1064436)	1.00	5/20
Hydrochloric Acid (SCHEMBL1165673)	0.97	5/20
Hydrochloric Acid (SCHEMBL1165266)	0.72	5/20
SCHEMBL566377	0.71	5/20
Hydrochloric Acid (SCHEMBL574657)	0.70	5/20
SCHEMBL567383	0.69	5/20
Hydrochloric Acid (SCHEMBL1165287)	0.68	5/20
Hydrochloric Acid (SCHEMBL566393)	0.68	5/20
SCHEMBL566378	0.66	5/20
SCHEMBL566379	0.66	5/20

Clinical trials — most relevant to PRKACG by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparison of the Postoperative Use of Dextenza vs a Standard Regimen After PRK	PHASE4	UNKNOWN
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds	PHASE2/PHASE3	COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Metformin for Fibromyalgia Symptoms (INFORM Trial)	PHASE2	RECRUITING
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer	PHASE2	COMPLETED
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	nan	COMPLETED
Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure	nan	COMPLETED
Exome Evaluation in Patients Living With Diabetes Complicated by Charcot Neuroarthropathy.	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
IL-17 Role in Variants of Psoriasis	nan	COMPLETED
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Hypotaurine Supplementation Benefits in Cryopreservation	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PRKACG binder may also engage these)

Protein	Name	Similarity
P68182	—	1.000	P68182 →
P68181	—	1.000	P68181 →
P05131	—	0.998	P05131 →
P05383	—	0.997	P05383 →
P68180	—	0.997	P68180 →
P12370	—	0.996	P12370 →
Q8MJ44	—	0.996	Q8MJ44 →
A8XW88	—	0.995	A8XW88 →
PRKACA	cAMP-dependent protein kinase catalytic subunit alpha	0.994	landscape →
PRKACB	cAMP-dependent protein kinase catalytic subunit beta	0.994	landscape →
Q9MZD9	—	0.992	Q9MZD9 →
P27791	—	0.991	P27791 →
P05132	—	0.991	P05132 →
P00517	—	0.991	P00517 →
P25321	—	0.990	P25321 →
P36887	—	0.989	P36887 →
Q922R0	—	0.987	Q922R0 →
O62846	—	0.985	O62846 →
PRKX	cAMP-dependent protein kinase catalytic subunit PRKX	0.983	landscape →
P21137	—	0.981	P21137 →
P49673	—	0.975	P49673 →
PRKCB	Protein kinase C beta type	0.975	landscape →
Q8R4U9	—	0.974	Q8R4U9 →
P54644	—	0.974	P54644 →
PRKCA	Protein kinase C alpha type	0.972	landscape →
Q16974	—	0.971	Q16974 →
P04409	—	0.970	P04409 →
P10102	—	0.970	P10102 →
Q9QZS5	—	0.970	Q9QZS5 →
A8KBH6	—	0.970	A8KBH6 →